Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc (SNDX) Options Open Interest
SNDX options open interest is 13,522 contracts. The 2-week average daily volume is 765 contracts across the chain.
Read more
Monitoring SNDX open interest helps you see where real money is positioned on Syndax Pharmaceuticals Inc's options and which strikes are attracting the most commitment from traders. Syndax Pharmaceuticals Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor SNDX options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising SNDX options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Syndax Pharmaceuticals Inc to settle.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat.
It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where SNDX open interest is concentrated. Our scanner maps Syndax Pharmaceuticals Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Syndax Pharmaceuticals Inc's options open interest as the signal it is, not as an afterthought.
| 25.00 | 0.10 | 1.95 | 1.03 | 157% | +0.2770 | 2,317 |
| 22.00 | — | 0.35 | 0.35 | 77% | +0.1941 | 513 |
| 20.00 | 0.15 | 0.85 | 0.50 | 61% | +0.3015 | 265 |
| 21.00 | — | 0.45 | 0.45 | 72% | +0.2479 | 238 |
| 30.00 | — | 2.15 | 2.15 | 271% | +0.3538 | 50 |
| 17.00 | — | 0.80 | 0.80 | 74% | -0.3216 | 141 |
| 12.00 | — | 0.25 | 0.25 | 132% | -0.0787 | 126 |
| 15.00 | — | 0.45 | 0.45 | 93% | -0.1735 | 115 |
| 18.00 | — | 1.50 | 1.50 | 88% | -0.4333 | 43 |
| 21.00 | 1.90 | 4.50 | 3.20 | 71% | -0.7562 | 43 |
As of September 22, 2026
Follow the money
Track SNDX open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→